The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation

Scientific Reports
Ibrahim El-SerafiM Hassan

Abstract

Busulphan (Bu) is a myeloablative drug used for conditioning prior to hematopoietic stem cell transplantation. Bu is predominantly metabolized through glutathione conjugation, a reaction that consumes the hepatic glutathione. N-acetyl-l-cysteine (NAC) is a glutathione precursor used in the treatment of acetaminophen hepatotoxicity. NAC does not interfere with the busulphan myeloablative effect. We investigated the effect of NAC concomitant treatment during busulphan conditioning on the liver enzymes as well as the clinical outcome. Prophylactic NAC treatment was given to 54 patients upon the start of busulphan conditioning. These patients were compared with 54 historical matched controls who did not receive NAC treatment. In patients treated with NAC, aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) were significantly (P < 0.05) decreased after conditioning compared to their start values. Within the NAC-group, liver enzymes were normalized in those patients (30%) who had significantly high start values. No significant decrease in enzyme levels was observed in the control group. Furthermore, NAC affected neither Bu kinetics nor clinical outcome (sinusoidal obstruction syndrome incidence, gr...Continue Reading

References

Jan 1, 1989·European Journal of Clinical Pharmacology·M HassanB Simonsson
Oct 1, 1988·European Journal of Drug Metabolism and Pharmacokinetics·M HassanS Eksborg
Jan 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·M Hassan, H Ehrsson
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G B McDonaldE D Thomas
Apr 1, 1997·Clinical Pharmacokinetics·E Masson, W C Zamboni
Feb 3, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·X WangL D DeLeve
Feb 15, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P A ChykaM I Herman
Jun 23, 2000·European Journal of Haematology·E Carreras
Sep 8, 2000·Clinical Pharmacokinetics·J S McCuneJ T Slattery
Aug 30, 2002·Blood·Tapani RuutuUNKNOWN Nordic Bone Marrow Transplantation Group
Dec 1, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Petter SvenbergOlle Ringdén
Feb 3, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Edoardo G GianniniVincenzo Savarino
Mar 10, 2005·Journal of Clinical Laboratory Analysis·Roger S RileyJonathan M Ben-Ezra
Jun 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeannine S McCuneGeorge B McDonald
Mar 4, 2008·JAMA : the Journal of the American Medical Association·Richard K BurtJohn Kessler
Feb 22, 2011·European Journal of Immunology·Helen KarlssonOlle Ringdén
Jan 8, 2013·Bone Marrow Transplantation·M AnsariUNKNOWN Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group
Apr 16, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrew R RezvaniGeorge B McDonald
Mar 13, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marie RobinNicolaus Kröger

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
biopsies

Software Mentioned

GraphPad
WinNonLin
GraphPad Prism
Systat
SigmaPlot

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.